{
    "2021-08-04": [
        [
            {
                "time": "",
                "original_text": "兴业证券：维持健帆生物(300529.SZ)“审慎增持”评级 产品线不断丰富 H1业绩实现良性增长",
                "features": {
                    "keywords": [
                        "健帆生物",
                        "审慎增持",
                        "产品线",
                        "H1业绩",
                        "良性增长"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医疗",
                        "生物科技"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "国泰君安：维持健帆生物(300529.SZ)“增持”评级 目标价104.28元",
                "features": {
                    "keywords": [
                        "健帆生物",
                        "增持",
                        "目标价"
                    ],
                    "sentiment_score": 0.65,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医疗",
                        "生物科技"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "71股获券商买入评级 天铁股份目标涨幅达77.96%",
                "features": {
                    "keywords": [
                        "券商买入评级",
                        "天铁股份",
                        "目标涨幅"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "其他行业"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "健帆生物(300529)：肾病整体稳健 肝病强势发力",
                "features": {
                    "keywords": [
                        "健帆生物",
                        "肾病",
                        "肝病",
                        "强势发力"
                    ],
                    "sentiment_score": 0.75,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医疗",
                        "生物科技"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "健帆生物(300529)2021年中报点评：灌流产品多线并举 H1业绩实现良性增长",
                "features": {
                    "keywords": [
                        "健帆生物",
                        "灌流产品",
                        "H1业绩",
                        "良性增长"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医疗",
                        "生物科技"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "电鳗快报|健帆生物业绩增四成 产品单一未改变 “集采”带来新风险",
                "features": {
                    "keywords": [
                        "健帆生物",
                        "业绩增四成",
                        "产品单一",
                        "集采",
                        "新风险"
                    ],
                    "sentiment_score": -0.5,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医疗",
                        "生物科技"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            }
        ]
    ]
}